ICUI

ICU Medical Inc

ICUI, USA

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. It offers infusion therapy products, such as needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

https://www.icumed.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ICUI
stock
ICUI

Price-Driven Insight from (ICUI) for Rule-Based Strategy news.stocktradersdaily.com

Read more →
ICUI
stock
ICUI

KeyBanc reiterates Overweight rating on ICU Medical stock, sees growth Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$180.8333

Analyst Picks

Strong Buy

3

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.71

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.16 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.08 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

5.15 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

0.93

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 124.49% of the total shares of ICU Medical Inc

1.

BlackRock Inc

(14.4337%)

since

2025/06/30

2.

Vanguard Group Inc

(10.7694%)

since

2025/06/30

3.

HHG PLC

(10.0064%)

since

2025/06/30

4.

iShares Core S&P Small-Cap ETF

(5.929%)

since

2025/08/31

5.

Fuller & Thaler Asset Management Inc

(5.6306%)

since

2025/06/30

6.

Janus Inst Mid Cap Growth CF

(4.9857%)

since

2025/06/30

7.

Janus Henderson Enterprise D

(4.9857%)

since

2025/06/30

8.

FullerThaler Behavioral Small-Cap Value

(4.9668%)

since

2025/06/30

9.

Undiscovered Managers Behavioral Val L

(4.7621%)

since

2025/07/31

10.

State Street Corp

(3.7584%)

since

2025/06/30

11.

JPMorgan Chase & Co

(3.0641%)

since

2025/06/30

12.

Dimensional Fund Advisors, Inc.

(3.0257%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(2.9652%)

since

2025/07/31

14.

River Road Asset Management, LLC

(2.6391%)

since

2025/06/30

15.

Schroder Investment Management Group

(2.5777%)

since

2025/06/30

16.

Geode Capital Management, LLC

(2.4471%)

since

2025/06/30

17.

Ameriprise Financial Inc

(2.4297%)

since

2025/06/30

18.

iShares Russell 2000 ETF

(2.3587%)

since

2025/08/31

19.

Vanguard Small Cap Index

(2.2994%)

since

2025/07/31

20.

Morgan Stanley - Brokerage Accounts

(2.1811%)

since

2025/06/30

21.

Neuberger Berman Group LLC

(2.1022%)

since

2025/06/30

22.

FMR Inc

(1.8269%)

since

2025/06/30

23.

Janus Henderson US SMID Cap Growth

(1.6694%)

since

2025/06/30

24.

Janus Henderson Triton D

(1.6694%)

since

2025/06/30

25.

Janus Henderson US SMID Cap Growth MA

(1.6694%)

since

2025/06/30

26.

Millennium Management LLC

(1.6136%)

since

2025/06/30

27.

Northern Trust Corp

(1.5743%)

since

2025/06/30

28.

Point72 Asset Management, L.P.

(1.5455%)

since

2025/06/30

29.

Vanguard Small Cap Value Index Inv

(1.4824%)

since

2025/07/31

30.

Silvercrest Asset Management Group LLC

(1.3378%)

since

2025/06/30

31.

Columbia Small Cap Growth

(1.3297%)

since

2025/06/30

32.

Bank of America Corp

(1.2576%)

since

2025/06/30

33.

Columbia Small Cap Growth Inst

(1.2489%)

since

2025/07/31

34.

Charles Schwab Investment Management Inc

(1.2416%)

since

2025/06/30

35.

JPMorgan Small Cap Equity A

(1.241%)

since

2025/07/31

36.

JPM US Small Cap Core-Composite

(1.241%)

since

2025/06/30

37.

JPM Small Cap Equity-MA

(1.241%)

since

2025/06/30

38.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0699%)

since

2025/07/31

39.

Fidelity Small Cap Index

(0.9826%)

since

2025/06/30

40.

Janus Henderson US Small Cap Growth

(0.9291%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.71

Latest Release

Date

2025-09-30

EPS Actual

2.03

EPS Estimate

1.42

EPS Difference

0.61

Surprise Percent

42.9577%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.